Drug Trial Radar · NCT04379869
To Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNZ-2591 in Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Jul 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
May 29, 2020
Primary completion
Feb 11, 2021
Study completion Feb 11, 2021
Sponsor
- Lead sponsor
- Neuren Pharmaceuticals LimitedIndustry
- Sponsor type
- Industry
- First posted
- May 8, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of NNZ-2591 when administered to healthy volunteers.
Conditions
- Healthy Volunteers
Interventions
NNZ-2591Drug
Single dose of NNZ-2591
PlaceboDrug
Comparator for double-blind MAD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability measured through Adverse Events /Serious Adverse EventsTime frame: 25 days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Scientia Clinical Research
Sydney, New South Wales, Australia
Linear Clinical Research, The Queen Elizabeth II Medical Centre
Nedlands, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.